results cardioversion analysis nonrheumatic disease cardioversion. of revealed that (p=0.03) increased arrhythmia arrhythmia free period. electrical duration, type Rheumatic heart of arrhythmia disease decreased in and age arrhythmia free period chronic independently (p=0.03) AF or influenced atrial conversion flutter, rate. and to 42 and 36% of pts remained factors in sinus rhythm during g clinical 1 and 2 y, outcome respectively. of the Multivariate regression after analysis revealed that the type of arrhythmia), low functional class and the presence of nonrheumatic mitral valve disease independently increased the length of the episode. Rheumatic heart disease shortened this period. Kingma 90 Conversion to Conversion to Consecutive pts w/ AF More than 1st degree Conversion to QRS widening N/A Recent onset AF Flecainide is JH w NSR w/in 1 hr NSR w/in 1 hr or flutter AV block, class I NSR in: occurred in flecainide more effective more effective 1992 meds: of start of of start of antiarrhtyhmics, 32/37 (86%) than propafenone at than (185) infusion: infusion: WPW syndrome, AF w/ pts conversion ((p<0.05) propafenone First 40: Second 50: SSS, AMI, flecainide (83±15 to Flutter conversion no at converting flecainide and flecainide and hyperthyroidism, 11/20 (55%) 99±20 msec; difference in conversion recent onset verapamil propafenone cardiac surgery <2 AF w/ PPF p<0.001), but w/ flecainide vs. AF, but not study assessed compared wk, left atrial In recent not after propafenone (p=NS) flutter. design. enlargement with AF onset AF, propafenone Verapamil ineffective. Verapamil
results of electrical in chronic AF or atrial flutter, and to factors clinical outcome of the after cardioversion analysis revealed that arrhythmia duration, type of arrhythmia and age independently influenced conversion rate. 42 and 36% of pts remained in sinus rhythm during 1 and 2 y, respectively. Multivariate regression analysis revealed that the type of arrhythmia), low functional class and the presence of nonrheumatic mitral valve disease independently increased the length of the episode. Rheumatic heart disease shortened this period. nonrheumatic disease (p=0.03) increased arrhythmia free period. Rheumatic heart disease decreased arrhythmia free period (p=0.03) cardioversion. Kingma JH 1992 (185) w meds: study design. 90 Conversion to NSR w/in 1 hr of start of infusion: First 40: flecainide and verapamil assessed Conversion to NSR w/in 1 hr of start of infusion: Second 50: flecainide and propafenone compared Consecutive pts w/ AF or flutter More than 1st degree AV block, class I antiarrhtyhmics, WPW syndrome, SSS, AMI, hyperthyroidism, cardiac surgery <2 wk, left atrial enlargement with AF Conversion to NSR in: 32/37 (86%) AF w/ flecainide 11/20 (55%) AF w/ PPF In recent onset AF, QRS widening occurred in pts (83±15 to 99±20 msec; p<0.001), but not after propafenone N/A Recent onset AF flecainide more effective than propafenone at conversion ((p<0.05) Flutter conversion no difference in conversion w/ flecainide vs. propafenone (p=NS) Verapamil ineffective. Flecainide is more effective than propafenone at converting recent onset AF, but not flutter. Verapamil g